Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04582487	Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL	unknown	N/A	32	Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER	1	Feb 7, 2024	clinicaltrials
NCT05821192	Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.	unknown	N/A	34	Ou Bai, MD/PHDOTHER	1	Apr 20, 2023	clinicaltrials